{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,2]],"date-time":"2025-11-02T16:45:44Z","timestamp":1762101944956},"reference-count":25,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2016,12,6]],"date-time":"2016-12-06T00:00:00Z","timestamp":1480982400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2016,12,6]],"date-time":"2016-12-06T00:00:00Z","timestamp":1480982400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Conbercept is a recombinant fusion protein with high affinity for all vascular endothelial growth factor isoforms and placental growth factor. The repeated intravitreal injection of conbercept may cause intraocular pressure (IOP) fluctuations and long-term suppression of neurotrophic cytokines, which could lead to retinal nerve fiber layer (RNFL) damage. This retrospective fellow-eye controlled study included 98 eyes of 49 patients. The changes in IOP and RNFL thickness as well as the correlation between RNFL changes and associated factors were evaluated. The IOP value between the baseline and the last follow-up visit in the injection group and the IOP value of the last follow-up visit between the injection and non-injection groups were not significantly different (p\u2009=\u20090.452 and 0.476, respectively). The global average thickness of the RNFL (\u03bcm) in the injection group decreased from 108.9 to 106.1; however, the change was not statistically significant (p\u2009=\u20090.118). No significant difference in the average RNFL thickness was observed at the last follow-up visit between the injection and non-injection groups (p\u2009=\u20090.821). The type of disease was the only factor associated with RNFL thickness changes. In conclusion, repeated intravitreal injections with 0.05\u2009mL conbercept revealed an excellent safety profile for RNFL thickness, although short-term IOP changes were observed.<\/jats:p>","DOI":"10.1038\/srep38326","type":"journal-article","created":{"date-parts":[[2016,12,6]],"date-time":"2016-12-06T11:32:03Z","timestamp":1481023923000},"update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Changes in Retinal Nerve Fiber Layer Thickness after Multiple Injections of Novel VEGF Decoy Receptor Conbercept for Various Retinal Diseases"],"prefix":"10.1038","volume":"6","author":[{"given":"Zhihua","family":"Zhang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiaolu","family":"Yang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Huiyi","family":"Jin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuan","family":"Qu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuan","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kun","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xun","family":"Xu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2016,12,6]]},"reference":[{"key":"BFsrep38326_CR1","doi-asserted-by":"publisher","first-page":"558","DOI":"10.1016\/j.ajo.2010.04.029","volume":"150","author":"MB Horsley","year":"2010","unstructured":"Horsley, M. B., Mandava, N., Maycotte, M. A. & Kahook, M. Y. Retinal nerve fiber layer thickness in patients receiving chronic anti-vascular endothelial growth factor therapy. Am J Ophthalmol. 150, 558\u2013561.e1 (2010).","journal-title":"Am J Ophthalmol"},{"key":"BFsrep38326_CR2","doi-asserted-by":"publisher","first-page":"1351","DOI":"10.1016\/j.ophtha.2016.02.022","volume":"123","author":"JA Wells","year":"2016","unstructured":"Wells, J. A. et al. Aflibercept, bevacizumab, or ranibizumab for diabetic macular edema: two-year results from a comparative effectiveness randomized clinical trial. Ophthalmology. 123, 1351\u20131359 (2016).","journal-title":"Ophthalmology."},{"key":"BFsrep38326_CR3","doi-asserted-by":"publisher","first-page":"1798","DOI":"10.1167\/iovs.15-18404","volume":"57","author":"HJ Shin","year":"2016","unstructured":"Shin, H. J., Kim, S. N., Chung, H., Kim, T. E. & Kim, H. C. Intravitreal anti-vascular endothelial growth factor therapy and retinal nerve fiber layer loss in eyes with age-related macular degeneration: a meta-analysis. Invest Ophthalmol Vis Sci. 57, 1798\u20131806 (2016).","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"BFsrep38326_CR4","first-page":"211","volume":"6","author":"G Sobac\u0131","year":"2013","unstructured":"Sobac\u0131, G., G\u00fcng\u00f6r, R. & Ozge, G. Effects of multiple intravitreal anti-VEGF injections on retinal nerve fiber layer and intraocular pressure: a comparative clinical study. Int J Ophthalmol. 6, 211\u2013215 (2013).","journal-title":"Int J Ophthalmol"},{"key":"BFsrep38326_CR5","doi-asserted-by":"publisher","first-page":"2403","DOI":"10.1167\/iovs.13-13769","volume":"55","author":"HJ Shin","year":"2014","unstructured":"Shin, H. J., Shin, K. C., Chung, H. & Kim, H. C. Change of retinal nerve fiber layer thickness in various retinal diseases treated with multiple intravitreal antivascular endothelial growth factor. Invest Ophthalmol Vis Sci. 55, 2403\u20132411 (2014).","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"BFsrep38326_CR6","doi-asserted-by":"publisher","first-page":"87","DOI":"10.3109\/02713683.2014.917190","volume":"40","author":"S Demirel","year":"2015","unstructured":"Demirel, S., Batio\u011flu, F., \u00d6zmert, E. & Erenler, F. The effect of multiple injections of ranibizumab on retinal nerve fiber layer thickness in patients with age-related macular degeneration. Curr Eye Res. 40, 87\u201392 (2015).","journal-title":"Curr Eye Res"},{"key":"BFsrep38326_CR7","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1136\/bjophthalmol-2014-305149","volume":"99","author":"MK Schmid","year":"2015","unstructured":"Schmid, M. K. et al. Efficacy and adverse events of aflibercept, ranibizumab and bevacizumab in age-related macular degeneration: a trade-off analysis. Br J Ophthalmol. 99, 141\u2013146 (2015).","journal-title":"Br J Ophthalmol"},{"key":"BFsrep38326_CR8","doi-asserted-by":"publisher","first-page":"e70544","DOI":"10.1371\/journal.pone.0070544","volume":"8","author":"Q Wang","year":"2013","unstructured":"Wang, Q. et al. Novel VEGF decoy receptor fusion protein conbercept targeting multiple VEGF isoforms provide remarkable anti-angiogenesis effect in vivo. PLoS One. 8, e70544 (2013).","journal-title":"PLoS One."},{"key":"BFsrep38326_CR9","doi-asserted-by":"publisher","first-page":"1740","DOI":"10.1016\/j.ophtha.2014.03.026","volume":"121","author":"X Li","year":"2014","unstructured":"Li, X. et al. Safety and efficacy of conbercept in neovascular age-related macular degeneration: results from a 12-month randomized phase 2 study: AURORA study. Ophthalmology. 121, 1740\u20131747 (2014).","journal-title":"Ophthalmology."},{"key":"BFsrep38326_CR10","doi-asserted-by":"publisher","first-page":"926","DOI":"10.1097\/IAE.0000000000000875","volume":"36","author":"J Qu","year":"2016","unstructured":"Qu, J., Cheng, Y., Li. X., Yu, L. & Ke, X. Efficacy of intravitreal injection of conbercept in polypoidal choroidal vasculopathy: subgroup analysis of the Aurora study. Retina. 36, 926\u2013937 (2016).","journal-title":"Retina."},{"key":"BFsrep38326_CR11","doi-asserted-by":"publisher","first-page":"2610","DOI":"10.4103\/0366-6999.192779","volume":"129","author":"Y Cheng","year":"2016","unstructured":"Cheng, Y., Shi, X., Qu, J. F., Zhao, M. W. & Li, X. X. Comparison of the 1-year Outcomes of Conbercept Therapy between Two Different Angiographic Subtypes of Polypoidal Choroidal Vasculopathy. Chin Med J (Engl). 129, 2610\u20132616 (2016).","journal-title":"Chin Med J (Engl)"},{"key":"BFsrep38326_CR12","first-page":"2311","volume":"9","author":"X Lu","year":"2015","unstructured":"Lu, X. & Sun, X. Profile of conbercept in the treatment of neovascular age-related macular degeneration. Drug Des Devel Ther. 9, 2311\u20132320 (2015).","journal-title":"Drug Des Devel Ther"},{"key":"BFsrep38326_CR13","doi-asserted-by":"publisher","first-page":"930","DOI":"10.1016\/j.ajo.2008.07.007","volume":"146","author":"JE Kim","year":"2008","unstructured":"Kim, J. E., Mantravadi, A. V., Hur, E. Y. & Covert, D. J. Short-term intraocular pressure changes immediately after intravitreal injections of anti-vascular endothelial growth factor agents. Am J Ophthalmol. 146, 930\u2013934.e1 (2008).","journal-title":"Am J Ophthalmol"},{"key":"BFsrep38326_CR14","doi-asserted-by":"publisher","first-page":"266","DOI":"10.1097\/IJG.0b013e3182071cdd","volume":"21","author":"BB Tan","year":"2012","unstructured":"Tan, B. B., Natividad, M., Chua, K. C. & Yip, L. W. Comparison of retinal nerve fiber layer measurement between 2 spectral domain OCT instruments. J Glaucoma. 21, 266\u2013273 (2012).","journal-title":"J Glaucoma."},{"key":"BFsrep38326_CR15","doi-asserted-by":"publisher","first-page":"1379","DOI":"10.1016\/j.ajpath.2012.12.032","volume":"182","author":"RH Foxton","year":"2013","unstructured":"Foxton, R. H. et al. VEGF-A is necessary and sufficient for retinal neuroprotection in models of experimental glaucoma. Am J Pathol. 182, 1379\u20131390 (2013).","journal-title":"Am J Pathol"},{"key":"BFsrep38326_CR16","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1016\/j.expneurol.2010.10.015","volume":"227","author":"T Murakami","year":"2011","unstructured":"Murakami, T. et al. Placental growth factor-2 gene transfer by electroporation restores diabetic sensory neuropathy in mice. Exp Neurol. 227, 195\u2013202 (2011).","journal-title":"Exp Neurol."},{"key":"BFsrep38326_CR17","doi-asserted-by":"publisher","first-page":"53","DOI":"10.2353\/ajpath.2007.061237","volume":"171","author":"K Nishijima","year":"2007","unstructured":"Nishijima, K. et al. Vascular endothelial growth factor-A is a survival factor for retinal neurons and a critical neuroprotectant during the adaptive response to ischemic injury. Am J Pathol. 171, 53\u201367 (2007).","journal-title":"Am J Pathol"},{"key":"BFsrep38326_CR18","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1002\/jnr.23316","volume":"92","author":"Y Inoue","year":"2014","unstructured":"Inoue, Y. et al. Protective effects of placental growth factor on retinal neuronal cell damage. J Neurosci Res. 92, 329\u2013337 (2014).","journal-title":"J Neurosci Res"},{"key":"BFsrep38326_CR19","doi-asserted-by":"publisher","first-page":"1119","DOI":"10.1016\/j.ophtha.2009.01.004","volume":"116","author":"KR Sung","year":"2009","unstructured":"Sung, K. R. et al. Effects of age on optical coherence tomography measurements of healthy retinal nerve fiber layer, macula, and optic nerve head. Ophthalmology. 116, 1119\u20131124 (2009).","journal-title":"Ophthalmology."},{"key":"BFsrep38326_CR20","doi-asserted-by":"publisher","first-page":"3660","DOI":"10.1167\/iovs.09-5041","volume":"51","author":"HW van Dijk","year":"2010","unstructured":"van Dijk, H. W. et al. Decreased retinal ganglion cell layer thickness in patients with type 1 diabetes. Invest Ophthalmol Vis Sci. 51, 3660\u20133665 (2010).","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"BFsrep38326_CR21","doi-asserted-by":"publisher","first-page":"e106","DOI":"10.1111\/j.1464-5491.2012.03588.x","volume":"29","author":"AM Shahidi","year":"2012","unstructured":"Shahidi, A. M. et al. Retinal nerve fiber layer thinning associated with diabetic peripheral neuropathy. Diabet Med. 29, e106\u2013111 (2012).","journal-title":"Diabet Med"},{"key":"BFsrep38326_CR22","doi-asserted-by":"publisher","first-page":"2790","DOI":"10.1167\/iovs.14-15145","volume":"56","author":"MA Shariati","year":"2015","unstructured":"Shariati, M. A., Park, J. H. & Liao, Y. J. Optical coherence tomography study of retinal changes in normal aging and after ischemia. Invest Ophthalmol Vis Sci. 56, 2790\u20132797 (2015).","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"BFsrep38326_CR23","doi-asserted-by":"publisher","first-page":"599","DOI":"10.2147\/OPTH.S58413","volume":"8","author":"QK Farhood","year":"2014","unstructured":"Farhood, Q. K. & Twfeeq, S. M. Short-term intraocular pressure changes after intravitreal injection of bevacizumab in diabetic retinopathy patients. Clin Ophthalmol. 8, 599\u2013604 (2014).","journal-title":"Clin Ophthalmol"},{"key":"BFsrep38326_CR24","doi-asserted-by":"crossref","unstructured":"VEGF Inhibition Study in Ocular Neovascularization (V.I.S.I.O.N.) Clinical Trial Group et al. Pegaptanib sodium for neovascular age-related macular degeneration: two-year safety results of the two prospective, multicenter, controlled clinical trials. Ophthalmology. 113, 992\u20131001 (2006).","DOI":"10.1016\/j.ophtha.2006.02.027"},{"key":"BFsrep38326_CR25","doi-asserted-by":"publisher","first-page":"1523","DOI":"10.1001\/archophthalmol.2010.297","volume":"128","author":"MP Frenkel","year":"2010","unstructured":"Frenkel, M. P., Haji, S. A. & Frenkel, R. E. Effect of prophylactic intraocular pressure-lowering medication on intraocular pres- sure spikes after intravitreal injections. Arch Ophthalmol. 128, 1523\u20131527 (2010).","journal-title":"Arch Ophthalmol."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/srep38326.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/srep38326","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/srep38326.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,1,5]],"date-time":"2023-01-05T00:56:53Z","timestamp":1672880213000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/srep38326"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,12,6]]},"references-count":25,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2016,12,23]]}},"alternative-id":["BFsrep38326"],"URL":"https:\/\/doi.org\/10.1038\/srep38326","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,12,6]]},"assertion":[{"value":"13 April 2016","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 November 2016","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 December 2016","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing financial interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"38326"}}